Valeant's Hostile Bid For Cephalon
Executive Summary
Valeant's hostile bid for Cephalon is a rejection of the traditional high risk, high reward R&D model employed by biopharma.
You may also be interested in...
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
Biotech executives make strategic decisions based on incentives that aren't necessarily aligned to benefit either the company's investors or employees. Three modifications to business as usual would help solve the problem and lead to improvements in the productivity of people and capital in the sector.
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
Biotech executives make strategic decisions based on incentives that aren't necessarily aligned to benefit either the company's investors or employees. Three modifications to business as usual would help solve the problem and lead to improvements in the productivity of people and capital in the sector.
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.